Investigational drug · Phase 2
quaratusugene ozeplasmid
Also called: REQORSA
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Carcinoma, Non-Small Cell Lung, Small Cell Lung Cancer Extensive Stage.
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "quaratusugene ozeplasmid"
First trial start
2021
Sep 3, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "quaratusugene ozeplasmid", any sponsor or status.
Conditions studied
As listed on its trial records.
- Carcinoma, Non-Small Cell Lung
- Small Cell Lung Cancer Extensive Stage
Approved drugs for the same conditions: Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "quaratusugene ozeplasmid" as an intervention, largest first.
- Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on OsimertinibPivotal-lookingRecruiting
Genprex, Inc.Industry
NCT04486833 · 158 participants (planned) · Start Sep 3, 2021 · Primary completion Mar 2028
Drug: quaratusugene ozeplasmid; osimertinib and 1 more · For: Carcinoma, Non-Small Cell Lung
Sites: Los Angeles, California; Lone Tree, Colorado; Urbana, Illinois · 10 sites in all
- Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC PatientsRecruiting
Genprex, Inc.Industry
NCT05703971 · 62 participants (planned) · Start May 9, 2024 · Primary completion Dec 2027
Drug: quaratusugene ozeplasmid; atezolizumab · For: Small Cell Lung Cancer Extensive Stage
Sites: Lone Tree, Colorado; St Louis, Missouri; Canton, Ohio · 17 sites in all
Genprex, Inc.Industry
NCT05062980 · 5 participants · Start Mar 30, 2022 · Primary completion Feb 3, 2025
Drug: quaratusugene ozeplasmid; pembrolizumab and 3 more · For: Non Small Cell Lung Cancer
Sites: Tampa, Florida; New Orleans, Louisiana; St Louis, Missouri · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Dose Escalation Trial of the Combination of Osimertinib and Quaratusugene Ozeplasmid Gene Therapy in Patients with Advanced NSCLC.
Spira AI, Berz D, Jotte RM, et al. · Clin Lung Cancer 2026
Also in development for Carcinoma, Non-Small Cell Lung
- Sigvotatug VedotinSGN-B6A, PF-08046047Phase 33 trials
Pfizer · Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
- PF-08046054SGN-PDL1VPhase 32 trials
Pfizer · Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.